Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction
NCT ID: NCT05537675
Last Updated: 2023-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2022-10-01
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
20 patients with meningioma
20 meningioma patients will be included in this study, 10 of whom will have been treated with Lutathera®.
To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
10 patients will have been treated with Lutathera®.
10 patients of the 20 will have been treated with Lutathera®.
To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antoine VERGER
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Sophie HUE, MSc
Role: STUDY_DIRECTOR
CHRU Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nuclear medicine Department CHRU de NANCY
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022PI
Identifier Type: -
Identifier Source: org_study_id